secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-10-06T21:15:44+00:00
Accession:  0001140361-26-038818
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Rocket Pharmaceuticals secures up to $150M credit facility from Hercules Capital; $35M drawn at close
--------------------------------------------------------------------------------

- Credit facility with Hercules Capital provides up to $150M: $35M funded Sept 30, 2026; $20M and $15M available through mid-2027; $30M on Danon milestone; $50M subject to Hercules approval.
- Interest at greater of prime or 6.75% plus 2.40%; interest-only through April 1, 2029, extendable to Oct 1, 2030 if FDA approves RP-A501 BLA for Danon disease; matures Oct 1, 2030.
- Warrants issued to Lenders for up to 1,755,853 shares at $2.99/share; 409,699 exercisable after Tranche 1-A; fully exercisable only if $150M fully drawn.
- Rocket had $283.7M cash as of June 30, 2026; with $35M initial draw, runway into Q3 2028; additional draws could extend into 2029.
- Proceeds support pivotal Phase 2 study of RP-A501 for Danon disease and cardiovascular pipeline; CEO cites priority review voucher sale as diversifying capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/0001140361-26-038818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/ef20083350_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-038818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer